Literature DB >> 8223853

Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes.

H Koeppen1, M Acena, A Drolet, D A Rowley, H Schreiber.   

Abstract

A murine solid tumor was transfected to express various levels of an allogeneic major histocompatibility complex class I gene (K216), in order to test the effect of the level of antigen expression on immunogenicity and sensitivity to lysis by cytotoxic T lymphocytes (CTL). The growth rates of clones of tumor cells expressing different levels of the transfected gene were similar in vitro and in nude mice. Although all tumor cells, including cells freshly isolated from growing tumors, were equally sensitive to lysis by specific CTL, only tumor cells expressing the highest level of the K216 antigen stimulated CTL and were rejected by normal mice. In contrast, tumor cells expressing lower levels of antigen failed to immunize for CTL and grew progressively in normal mice, despite retaining expression of the transfected gene and remaining fully sensitive to CTL-mediated lysis; thus, the threshold of antigen needed to stimulate CTL responses was considerably higher than that needed to lyse tumor cells. Reduction of K216 antigen expression from 100-fold to 40-fold above background, impaired significantly the ability of the tumor cells to induce a K216-specific immune response, while tumor cells expressing K216 at levels 2-fold above background were as susceptible to CTL-mediated lysis as tumor cells expressing 50-fold more antigen. The important implication of these findings is that some tumors occurring in nature may not be immunogenic but nevertheless express antigens which are potential targets for immune therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223853     DOI: 10.1002/eji.1830231108

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy.

Authors:  S Pion; P Fontaine; C Baron; M Gyger; C Perreault
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

2.  Immunogenicity and immunosensitivity of ex vivo human carcinomas: interferon gamma and tumour necrosis factor alpha treatment of tumour cells potentiates their interaction with autologous blood lymphocytes.

Authors:  F Vánky; C Hising; K Sjöwall; B Larsson; L Rodriguez; L Orre; E Klein
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

3.  Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.

Authors:  Bin Zhang; Natalie A Bowerman; Joseph K Salama; Hank Schmidt; Michael T Spiotto; Andrea Schietinger; Ping Yu; Yang-Xin Fu; Ralph R Weichselbaum; Donald A Rowley; David M Kranz; Hans Schreiber
Journal:  J Exp Med       Date:  2007-01-08       Impact factor: 14.307

4.  Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy.

Authors:  M Wick; P Dubey; H Koeppen; C T Siegel; P E Fields; L Chen; J A Bluestone; H Schreiber
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

5.  B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.

Authors:  J V Johnston; A R Malacko; M T Mizuno; P McGowan; I Hellström; K E Hellström; H Marquardt; L Chen
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.